Comparative Pharmacology
Head-to-head clinical analysis: ACTOPLUS MET XR versus PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACTOPLUS MET XR versus PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE.
ACTOPLUS MET XR vs PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ACTOPLUS MET XR combines pioglitazone, a thiazolidinedione that improves insulin sensitivity by activating PPAR-γ, and metformin, a biguanide that decreases hepatic glucose production and improves peripheral glucose uptake.
Pioglitazone is a thiazolidinedione that acts as an agonist at peroxisome proliferator-activated receptor-gamma (PPAR-γ), increasing insulin sensitivity in adipose tissue, skeletal muscle, and liver. Metformin is a biguanide that decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.
Initial dose: 15 mg pioglitazone/500 mg metformin hydrochloride extended-release orally once daily with evening meal. Titrate based on glycemic response, maximum dose 45 mg pioglitazone/2000 mg metformin hydrochloride extended-release per day.
Initial: 15 mg pioglitazone/500 mg metformin twice daily or 30 mg pioglitazone/500 mg metformin once daily. Titrate gradually based on glycemic response. Maximum: 45 mg pioglitazone/2000 mg metformin per day in divided doses.
None Documented
None Documented
Pioglitazone: terminal half-life 3-7 hours (parent), 16-24 hours (active metabolites); clinical effect sustained due to metabolites. Metformin: terminal half-life 6.2 hours (plasma), elimination prolonged in renal impairment (creatinine clearance <60 mL/min).
Metformin: 6.2 hours (increased in renal impairment). Pioglitazone: 3-7 hours (parent), 16-24 hours (active metabolites), requiring once-daily dosing.
Pioglitazone: predominantly hepatic metabolism, 15-30% excreted in urine as metabolites, ~20% in feces. Metformin: 90% renal excretion unchanged via glomerular filtration and tubular secretion.
Metformin: 90% renal (unchanged), 10% fecal. Pioglitazone: 60-70% renal (metabolites), 20-30% fecal.
Category C
Category A/B
Thiazolidinedione/Biguanide Combination
Thiazolidinedione